JP2014520147A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520147A5
JP2014520147A5 JP2014517091A JP2014517091A JP2014520147A5 JP 2014520147 A5 JP2014520147 A5 JP 2014520147A5 JP 2014517091 A JP2014517091 A JP 2014517091A JP 2014517091 A JP2014517091 A JP 2014517091A JP 2014520147 A5 JP2014520147 A5 JP 2014520147A5
Authority
JP
Japan
Prior art keywords
use according
benzo
dihydroisoxazol
methylcarbamoyl
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014517091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520147A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/043150 external-priority patent/WO2012177640A2/en
Publication of JP2014520147A publication Critical patent/JP2014520147A/ja
Publication of JP2014520147A5 publication Critical patent/JP2014520147A5/ja
Pending legal-status Critical Current

Links

JP2014517091A 2011-06-20 2012-06-19 疾患における組織トランスグルタミナーゼ活性化の調節 Pending JP2014520147A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161499044P 2011-06-20 2011-06-20
US61/499,044 2011-06-20
PCT/US2012/043150 WO2012177640A2 (en) 2011-06-20 2012-06-19 Modulation of tissue transglutaminase activation in disease

Publications (2)

Publication Number Publication Date
JP2014520147A JP2014520147A (ja) 2014-08-21
JP2014520147A5 true JP2014520147A5 (enExample) 2015-08-13

Family

ID=47423169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517091A Pending JP2014520147A (ja) 2011-06-20 2012-06-19 疾患における組織トランスグルタミナーゼ活性化の調節

Country Status (6)

Country Link
US (2) US20140322278A1 (enExample)
EP (1) EP2721169A4 (enExample)
JP (1) JP2014520147A (enExample)
AU (1) AU2012273105A1 (enExample)
CA (1) CA2839549A1 (enExample)
WO (1) WO2012177640A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015116846A1 (en) * 2014-01-30 2015-08-06 The Board Of Trustees Of The Leland Stanford Junior University Modulation of tissue transglutaminase activation in disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116496A1 (en) * 1996-12-06 2004-06-17 Lynn Kirkpatrick Asymmetric Disulfides and methods of using same
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
AU2003234597A1 (en) * 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US20040259176A1 (en) * 2003-02-25 2004-12-23 Cerione Richard A. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2010529118A5 (enExample)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2011522816A5 (enExample)
JP2010536849A5 (enExample)
FI3811943T3 (fi) Yhdiste käytettäväksi silmäsairauksien hoidossa
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
JP2011516477A5 (enExample)
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
JP2010222367A5 (enExample)
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL199152A (en) Annals 2 - (piperidine-4-ram) -4-phenoxy or phenylamino-pyrimidine, containing and containing pharmaceutical preparations for the preparation of viral infections
HRP20151000T1 (hr) Antivirusni spojevi
IL216741A (en) History of imidazolidine-2-van 1,3-imaging modalities as 17-cyp inhibitors, pharmaceutical preparations containing them, and their use in the preparation of drugs for the treatment of diseases
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
MX377802B (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
CL2007002347A1 (es) Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm
JP2009500443A5 (enExample)
JP2012136529A5 (enExample)
WO2008078424A1 (ja) ベンゾキサゾール誘導体
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
JP2020529995A5 (enExample)
HRP20241716T1 (hr) Postupci liječenja promjena u ponašanju
CL2007002195A1 (es) Compuesto n-((1r,2s,5r)-5-(isopropil(metil)amino)-2-((s)-2-oxo-3-(6-(trifluorometil)quinazolin-4-ilamino)pirrolidin-1-il)ciclohexil)acetamida; forma cristalina del compuesto; composicion farmaceutica; y uso en el tratamiento de enfermedades tales com
JP2015518007A5 (enExample)
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson